Prevalence and Clinical Characterization of Bocavirus Infection in a Specialized Children's Hospital in Saudi Arabia

Hamad Alkhalf 1, 2, 3, Ashqog R. Almutairi 4, Abeer Almutairi 5, Reem K. Almutairi 6, Suliman AlGhnam 7, Sameera AlJohani 8, 9, 10, Juilan T. Alqanatish 11, 2, 3, Amir Babiker 12, 2, 3

Abstract

Aim

The aim of this study was to assess the prevalence and clinical characterization of bocavirus infection in patients admitted with respiratory symptoms to a specialized children's hospital in Riyadh, Saudi Arabia.

Methods

This is a retrospective cross-sectional study that included children aged 0-14 years and was conducted over a two-year period (2017-2019). All data were gathered from an electronic information recording system, which included patients’ demographics, comorbidities, clinical presentation, complication, and duration of hospitalization.

Results

Among all patients (11,709) admitted to King Abdullah Specialized Children’s Hospital with predominant respiratory symptoms during the study period, 195 (1.6%) patients had bocavirus infections. Most of the patients were diagnosed in winter months. Cough was the primary presenting symptom (91.7%) followed by fever (83.4%). Gastrointestinal symptoms were also common (anorexia in 62% and vomiting in 39%). In 80% of patients were diagnosed in winter months. Cough was the primary presenting symptom (91.7%) followed by fever (83.4%). Gastrointestinal symptoms were also common (anorexia in 62% and vomiting in 39%). In 80%

Conclusion

Bocavirus infection is more common during winter months and predominantly affects respiratory and gastrointestinal systems in children. More studies are needed to evaluate the global impact of this recently recognized infection.

Keywords: Pediatrics, Infectious Disease, Pulmonology

Introduction

Bocavirus is a recently described virus that mainly affects lower respiratory and gastrointestinal tracts of children [1]. Bocavirus is a type of parvovirus family and is known to have a small size of 20 nm [1]. The name "bocavirus” is derived from a combination of bovine parvovirus and canine minute virus, which have similar genetic and amino acid structures [2]. Human bocavirus (HBoV) is non-enveloped with a single-stranded negative DNA virus [2]. Moreover, four strains of this virus have recently been identified: HBoV1, HBoV2, HBoV3, and HBoV4 [3]. HBoV1 has mainly been identified in respiratory specimens. Other types of bocavirus have been identified in stool specimens [3]. Moreover, bocavirus was also detected in urine, saliva, and blood, and had been identified in sewage and river water [2].
Bocavirus usually affects infants and children from six months to two years of age, although some cases have been found in children older than five years of age [1]. It can be detected alone or, more commonly, in conjunction with other viruses that cause respiratory or gastrointestinal infections such as human rhinovirus, adenovirus, norovirus, and rotavirus [4]. In particular, co-infection with respiratory syncytial virus (RSV) has been found in 89% of cases [5]. Therefore, it was thought that HBoV might be a harmless passenger rather than a true pathogen [5,6]. Bocavirus presents with non-specific symptoms such as cough, wheeze, pneumonia, and fever [5]. Also, especially with HBoV2 and HBoV3, it can present with acute gastroenteritis [3].

Rhinorrhea, asthma exacerbation, and bronchiolitis were detected in some young patients in conjunction with a progressive bocavirus infection [7]. Two of the rare and life-threatening conditions that bocavirus-infected children can develop are pneumomediastinum and bilateral pneumothorax [7]. HBoV is exclusively detected by molecular detection methods [8]. Currently, laboratories use either in-house polymerase chain reaction (PCR) or real-time PCR assays in order to detect the virus [8]. Moreover, the PCR method targets NP-1, NS-1, or VP1/2 genes, which are proteins or genes found on this virus [8,9]. Recently, some multiplexing assays have been developed, which are the RespiFinder assay (PathoFinder, Maastricht, the Netherlands) and the Luminex xTAG Respiratory Viral Panel (RVP) FAST v2 assay (Luminex Molecular Diagnostics, Toronto, ON, Canada) [1,9]. The latter has been approved by the U.S. Food and Drug Administration (FDA) [1,9]. So far, there is no antiviral medication known to treat HBoV [10]. Similar to many other viruses, supportive therapy to control symptoms remains the mainstay of treatment for HBoV [10]. This includes providing oxygen supply for hypoxia and the use of bronchodilators for patients with wheezes [1,10].

The first isolation of this virus was found in 2005 in upper respiratory secretions in acutely ill patients in Sweden [4]. The estimated worldwide rate of HBoV is 2-20%, but the true comparable rate cannot be detected due to lack of studies in different populations [1]. Locally, one study conducted in Al-Taif, a city in the western region of Saudi Arabia, determined the prevalence of bocavirus in 80 samples of nasopharyngeal swabs [11]. In this study, bocavirus had been detected in 22% (18/80), mainly in young children between five months and two years of age [11]. Our study aimed to examine the prevalence and clinical characteristics of bocavirus infection among children in Saudi Arabia to raise awareness about the disease among the health personnel in public health care authorities.

Materials And Methods

This is a retrospective cross-sectional study at King Abdullah Specialized Children’s Hospital (KASCH) in Riyadh, Saudi Arabia. We included all patients aged 0-14 years admitted as inpatients in KASCH with bocavirus infection who had respiratory, gastrointestinal, or other symptoms from November 2017 until November 2019. Data included all patients who tested positive for bocavirus, isolated or with co-infection. We excluded admissions in the emergency room and daycare unit during the study period. The estimated sample size was 660 patients using the online Raosoft sample size calculator. This was based on a precision of 10 percentage points of the true prevalence, with a confidence level of 95% and an expected prevalence of 22% [11]. However, we included all patients who met the inclusion criteria. The data were collected from an electronic health record system known as BestCare. The data collection sheet was designed to capture different variables including clinical and laboratory findings. Information about the level of baseline clinical comorbidities, duration of oxygen therapy, length of hospital stay (LOS), complications, and, lastly, mortality (if any) was also planned to be reported. The study was reviewed and approved by the Institutional Review Board of King Abdullah International Medical Research Center (KAIMRC).

Statistical analysis

The data were analyzed using SPSS (IBM Corp., Armonk, NY, USA). Data were presented as mean ± standard deviation (SD) for continuous variables and as percentages for categorical variables. The chi-square test or Fisher’s exact test was used to compare categorical data. A logistic regression was constructed to determine independent significant predictors of an extended hospitalization, defined as an LOS above the mean of 5.3 days. Odds ratios (OR) with 95% confidence intervals (CI) were expressed relative to a reference baseline category. A p-value of 0.05 was used as a cut-off for statistical significance.

Results

Among all patients (11,709) admitted to King Abdullah Specialist Children Hospital with respiratory illness during the study period, we included 195 (1.6%) patients who had bocavirus infections (Table 1). The frequency of reported symptoms and signs varied between patients with a mean of 6 ± 2 complaints and clinical findings per admitted child with bocavirus infection (Table 2). Patients were treated using variable medications according to their clinical presentation (Table 2). Analysis showed that there were at least 224 co-viral infections in 154 (80%) of children admitted with bocavirus infection, with the highest association with human rhinovirus (45%) and human adenovirus (50%). Other viruses with less co-infection association with bocavirus in our cohort include RSV (7%) and less than 5% for each of the following viruses: influenza and parainfluenza viruses, human coronavirus OC43 and NL63, Epstein Barr virus, and rotavirus. Of these patients with co-infections, 100 had one co-infection, 41 had two co-infections, 10 had three co-infections, and three patients had four co-infections.
|                                | Frequency | Percentage |
|--------------------------------|-----------|------------|
| **Sex**                        |           |            |
| Male                           | 102       | 52.8       |
| Female                         | 91        | 47.2       |
| **Age (months), mean (SD)**    | 23.04 (22.5) |          |
| Infant (0-11.9 months)         | 68        | 38.6       |
| Toddler (1-3 years)            | 75        | 42.6       |
| Pre-school aged (3.1-5 years)  | 23        | 13.1       |
| School aged (5.1-12 years)     | 8         | 4.5        |
| Adolescent (12.1-14 years)     | 2         | 1.1        |
| **Weight (kg), mean (SD)**     | 10.68 (5.4) |          |
| **Height (cm), mean (SD)**     | 80.27 (16.6) |        |
| **Body mass index, mean (SD)** | 15.73 (2.68) |        |
| **Age-adjusted BMI classification** |    |      |
| Underweight for age ≤ 5th percentile | 43 | 22.3 |
| Normal weight (>5th-90th percentile) | 117 | 60.6 |
| Over-weight >90% percentile     | 33        | 17.1       |
| **Length of hospital stay (days), mean (SD)** |    | |
| LOS≤5.3 days                   | 147       | 76.2       |
| LOS>5.3 days                   | 46        | 23.8       |
| **Comorbidity**                |           |            |
| No                             | 118       | 61.1       |
| Yes                            | 75        | 38.9       |
| **Year of admission**          |           |            |
| 2017                           | 17        | 8.8        |
| 2018                           | 111       | 57.5       |
| 2019                           | 65        | 33.7       |
| **Admission quarter of the year** |     |      |
| 1st quarter                    | 78        | 40.4       |
| 2nd quarter                    | 44        | 22.8       |
| 3rd quarter                    | 25        | 13         |
| 4th quarter                    | 46        | 23.8       |

**TABLE 1: Characteristics of study subjects (N=193)**

BMI, body mass index; LOS, length of hospital stay; SD, standard deviation
| Symptom                                                                 | Patients (%) | Severity (%) |
|------------------------------------------------------------------------|--------------|--------------|
| Cough                                                                  | 177          | 91.7         |
| Shortness of breath                                                    | 140          | 72.5         |
| Nasal discharge                                                        | 87           | 45.5         |
| Wheezing                                                               | 81           | 42           |
| Congested throat                                                       | 80           | 41.5         |
| Chest retractions using accessory muscles                              | 58           | 30.1         |
| Stridor                                                               | 7            | 3.6          |
| Cyanosis                                                               | 1            | 0.5          |
| Presenting gastrointestinal manifestations                              |              |              |
| Loss of appetite                                                       | 124          | 64           |
| Vomiting                                                               | 76           | 39.4         |
| Diarrhea                                                              | 25           | 13           |
| Abdominal pain                                                         | 1            | 0.5          |
| Splenomegaly                                                          | 1            | 0.5          |
| Presenting immune system manifestations                               |              |              |
| Fever                                                                  | 161          | 83.4         |
| Fatigue                                                                | 112          | 58           |
| Tonsillitis                                                           | 8            | 4.1          |
| Lymph node enlargement                                                 | 6            | 3.1          |
| Convulsions                                                           | 5            | 2.6          |
| Other body systems' presenting manifestations                          |              |              |
| Ear congestion                                                         | 12           | 6.2          |
| Conjunctivitis                                                         | 10           | 5.2          |
| Skin rash                                                              | 9            | 4.7          |
| Eye discharge                                                          | 3            | 1.6          |
| Ear discharge                                                          | 2            | 1            |
| Photophobia                                                           | 1            | 0.5          |
| Total symptoms and signs (severity), mean (SD)                         | 6.15 (1.84)  |              |
| Medical management                                                    |              |              |
| Bronchodilators                                                       | 148          | 77.5         |
| O₂ supplement (0.2-1.5 L/minute)                                       | 113          | 59.2         |
| Antibiotics                                                           | 111          | 58.1         |
| Antipyretics                                                          | 96           | 50.3         |
| Corticosteroids                                                       | 91           | 47.6         |
| Pain killers (NSAIDs)                                                  | 36           | 18.8         |
| Other medications                                                     | 28           | 14.7         |
| Racemic epinephrine (nebulized)                                        | 22           | 11.5         |
| Duration (hours) of supplemental O₂, mean (SD)                        | 10.74 (6.4)  |              |
| Other interventions                                                   |              |              |
Laboratory results indicate that the mean leukocytes count for the patients upon admission was normal (4.0 - 11.0 \times 10^9/L) in 73.6% of cases compared to 8.8% of children admitted with lower than (4.0 \times 10^9/L) white blood cell count. Moreover, the mean hemoglobin level (gm/L) was normal for age in 82.4% of cases. Additionally, serum glucose levels were higher than the normal range for age in the majority (89.6%) of children, but only 10.4% of them had normal blood glucose and none of them had low serum glucose level. The majority of children with bocavirus infection (76.2%) showed signs of hyponatremia with serum Na < 135 mmol/L. A smaller number of them had a normal serum Na+ level (135-145 mmol/L), and none of these patients had hypernatremia. Moreover, most of the children (64.8%) had a normal serum potassium level (K+) upon admission and 27.5% presented with hypokalemia. Few (7.8%) of these patients had hyperkalemia.

An overall average LOS for patients was 5.31 ± 7 days, with 75% of children stayed for five or less days in the hospital. Based on the mean score (LOS=5.3), we divided patients based on their LOS into two groups of short LOS (≤5.31 days) and extended LOS (>5.3 days). Furthermore, we described the quarterly admission of the children with respiratory complaints who were diagnosed with a positive bocavirus infection in order to identify any seasonal variations in the numbers of admissions per year, month, and quarter (Figure 1 and Table 1). Most of these cases appeared to occur during the first three months (i.e., the winter quarter) of the year, and fewer cases were seen during the summer quarter (June-August). The number climbed again during the fall quarter (i.e., between September and December) (Figure 1). The most common reported complication with bocavirus infection in our cohort was respiratory distress (Table 3).
| Complication                                      | Frequency | Percentage |
|--------------------------------------------------|-----------|------------|
| Respiratory distress                             | 75        | 94.9       |
| Dehydration                                      | 3         | 3.6        |
| Respiratory failure requiring ventilatory support| 2         | 2.5        |
| Pneumothorax                                     | 1         | 1.3        |
| Septic shock                                     | 1         | 1.3        |
| Superimposed lymphadenitis                       | 1         | 1.3        |

**TABLE 3: Measured complications of hospitalized children with bocavirus infection (N=79)**

Regression analyses identified comorbidities and the need for oxygenation during management as the significant predictors of extended LOS (> 5.3 days) (Table 4). After adjusting for age, gender, and body mass index (BMI), having at least one comorbidity was associated with a fourfold increased odd of extended stay (OR=4.5; 95% CI=2.1-9.5). Irrespective of age, gender, or BMI, patients who received oxygen therapy required as twice as the duration of hospital stay of those without oxygen requirement (OR=2.2; 95% CI=1.0-9.5).

**TABLE 4: Logistic regression model of the association between patients’ characteristics and extended hospital stay (defined as > 5.3 days)**

*Significant at 0.05 level

BMI, body mass index; CI, confidence interval; LOS, length of hospital stay; OR, odd ratio

**Discussion**

Bocavirus infection was less common in our study group compared to worldwide reports and previous prevalence studies in Saudi Arabia [11-16]. Affected children were of younger age group and were more prone to get infected during winter months. Respiratory symptoms were non-specific, but there were also gastrointestinal symptoms in most of our patients. In our tertiary institute, the majority of patients received oxygen, antibiotics, corticosteroids, and bronchodilators, but the LOS was relatively short in duration compared to other viruses.

HBoV has variable prevalence in different parts of the world [12-16]. Similar to the findings in previous international studies, our study showed low prevalence of bocavirus infection among inpatient children [9,17,18]. Nevertheless, in a previous study in Al Taif in Saudi Arabia, which lies in a high altitude (1.879 meters, 6.16 feet in the slopes of the Hejaz mountains), a notably higher prevalence of bocavirus infection of 22.5% was reported [11]. This could be related to more cool weather during winter season that enhances viral replication, which is the same cause of higher reports of the disease during winter months in our cohort [11]. On average, temperature in Riyadh ranges from 49°F to 110°F (rarely below 41°F or above 114°F). The age of children who were infected with bocavirus was lower in our study compared to a previous study in Al Qatif, Saudi Arabia [19]. However, our results were in keeping with the age distribution reported in most of the other studies with predominance in children less than 24 months old possibly related to suboptimal immune
response against the virus in this age group [4,9,20]. Unlike most of previous pediatric studies on bocavirus infection that reported male predominance, our study showed almost equal gender distribution [11,19,21]. Understandably, younger age group in our cohort, likewise in other studies, had more respiratory complaints compared to older age group. However, systemic symptoms and immunological manifestations such as fever, lymph node inflammation, body aches, and convulsions accompanying fever. Similar to many other viruses, bocavirus had the highest incidence in our study during winter and fall quarters of the year [4,17,18]. On the other hand, some studies found bocavirus to be detected more in the summer season [11,22]. Another study in China found that the incidence of bocavirus increased more during the spring and summer seasons (May-June 2010) [23].

Characterizing viral respiratory tract infections is difficult because various symptoms can be caused by a wide range of viruses. In all studies of bocavirus, including ours, researchers have agreed that bocavirus usually presents predominantly as a lower respiratory tract infection [21,25,24]. In consistence with other bocavirus studies, our study showed a significant rate of co-infection with other viruses [25-28]. The most common coexisting viruses in our study were human rhinovirus, human adenovirus, and RSV. This phenomenon could be explained by the fact that bocavirus weakened children’s immunity, and, therefore, children were more likely to get other infections, or it could be that the pathogenesis of bocavirus led to introduction of other viruses to the systems. Another possibility is that bocavirus is acting as a bridge for other viruses or it needed other virus(es) to replicate. Moreover, our study indicated that bocavirus could present with gastrointestinal symptoms such as vomiting and diarrhea, which have also been reported in previous studies [9,24,29]. However, the most common reason for hospital admission with bocavirus infection in children is respiratory distress. We found that 75/193 children we studied experienced respiratory distress of various degrees of severity. This was also observed in a study in Thailand, which showed that the bocavirus could cause severe respiratory distress that led to pneumonia [25]. An explanation of this could be due to the pathogenesis of bocavirus or because of the higher rate of co-infections. It could also be related to immaturity of the immune system in children younger than two years of age contributing to the severe forms of the infection [25,26]. In our study, bocavirus-infected children with predominantly pneumonia, bronchodilators followed by oxygen therapy. The mean oxygenation duration was 10.74 ± 6.4 hours on average. Children infected with bocavirus and co-existing viruses were less likely to require oxygen therapy in our study than those who are otherwise healthy, and that certainly adds to the prolonged LOS. Last but not least, at all times and especially in this era of post-COVID-19 pandemic, education about hand washing and other measures of infection control for parents and caregivers of hospitalized children should not be forgotten as this would certainly improve LOS.

Most patients had shorter LOS in our study. Another study in China also found that bocavirus-positive admitted patients had a short period of hospitalization compared to other common viruses [22]. The main predictors of extended LOS in our study were comorbidity and the requirement of oxygen treatment. A similar finding with regard to oxygenation being an influencing factor of LOS of children with bocavirus infection was reported in a previous study in California [30]. Interestingly, as also observed in a study in Brazil, children who received oxygen in our study were younger (infants and toddlers) and stay longer in the hospital with the bocavirus infection. When adjusted in our logistic regression analyses, the prolonged LOS was mainly related to the oxygen requirement but not to the age. Also, as expected, comorbid patients had a greater need for oxygen therapy in our study than those who are otherwise healthy, and that certainly adds to the prolonged LOS. Last but not least, at all times and especially in this era of post-COVID-19 pandemic, education about hand washing and other measures of infection control for parents and caregivers of hospitalized children should not be forgotten as this would certainly improve LOS.

Most patients received bronchodilators, antipyretics, antibiotics, and steroids in our study, irrespective of complexity level of their medical condition. The top administered medical therapy in our study was bronchodilators followed by oxygen therapy. The mean oxygenation duration was 10.74 ± 6.4 hours on average. Children infected with bocavirus and co-existing viruses were less likely to require oxygen supply. Although RSV is usually associated with oxygen requirement, it only coexisted with bocavirus infection in 7% of our cohort. Given this interesting observation the study lent on the oxygen requirement, the authors postulate that coexistence with other viruses probably resulted in a better immune response observed as more apparent constitutional symptoms in these patients. This could also hypothetically reduce the severity of bocavirus infection and related oxygen requirement in these patients. Steroids, specifically prednisolone, were not found effective in treating children with bocavirus [10]. Around 47% of our patients, however, were treated with steroids, and around 60% of those who received oxygen were also treated with steroids. Most of the children in our study were placed on at least one kind of antibiotic therapy during hospital admission despite the viral nature of the disease. An additional diagnosis of a possible bacterial infection such as otitis media or pneumonia in these patients has warranted the use of the antibiotic. However, the use of antibiotics was empirical in most of these patients based on the severity of presentation and suspicion of co-existing bacterial infection. Therefore, a stewardship antimicrobial program was implemented in our institute to minimize the overuse of antibiotics in such patients. Understandably, the majority of bocavirus admitted cases received anti-pyretic medications to relieve their fever.

A limitation of our study was that it was a single-center study conducted over a limited period of time. Probably, a larger multicenter study is required to evaluate the global impact of this virus over a longer period of time.

**Conclusions**
Bocavirus is a recently recognized virus that predominantly affects respiratory and gastrointestinal systems. Similar to other viruses, it tends to affect children more during winter months with a complicated course in vulnerable patients who have other comorbidities; hence, patients had a prolonged LOS in hospital. Oxygen and bronchodilators were commonly used modalities of management, and steroids were not found to be effective in our cohort.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. King Abdullah International Medical Research Centre issued approval RC/18/065/R. The study was reviewed and approved by the Institutional Review Board of King Abdullah International Medical Research Centre (KAIMRC). .

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Schildgen O: Human bocavirus: lessons learned to date . Pathogens. 2015, 2:1-12. 10.3390/pathogens2010001
2. Guido M, Tumolo MR, Verri T, et al.: Human bocavirus: current knowledge and future challenges . World J Gastroenterol. 2016, 22:864-97. 10.3748/wjg.v22.i19.8684
3. Jartti T, Hedman K, Jartti L, Ruuskanen O, Allander T, Söderlund-Venermo M: Human bocavirus-the first 5 years. Rev Med Virol. 2012, 22:46-64. 10.1002/rmv.720
4. Allander T, Tammi MT, Eriksson M, Björkner A, Tiveljung-Lindelöw A, Andersson B: Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005, 102:12891-6. 10.1073/pnas.0504666102
5. Christensen A, Nordha S, Kroksstad S, Rognlien AG, Dahlner H: Human bocavirus commonly involved in multiple viral airway infections. J Clin Virol. 2008, 41:54-7. 10.1016/j.jcv.2007.10.035
6. Debiaggi M, Candurci F, Cerboni ER, Clementi M: The role of infections and coinfections with newly identified and emerging respiratory viruses in children. Virol J. 2012, 9:247. 10.1186/1743-422X-9-247
7. Yesilbas O, Kiburt HS, Talip Petmezci M, Balkaya S, Hatipoğlu N, Meşe S, Şevketoğlu E: [Very rare and life-threatening complications of bocavirus bronchiolitis: pneumomediastinum and bilateral pneumothorax]. Mikrobiyol Bul. 2016, 50:159-64. 10.5578/mib.10512
8. Kantola K, Hedman L, Allander T, et al.: Serodiagnosis of human bocavirus infection. Clin Infect Dis. 2008, 46:540-6. 10.1086/526532
9. Schildgen O, Müller A, Allander T, Mackay IM, Vižs S, Kupfer B, Simon A: Human bocavirus: passenger or pathogen in acute respiratory tract infections?. Clin Microbiol Rev. 2008, 21:291-304, table of contents. 10.1128/CMR.00050-07
10. Jartti T, Söderlund-Venermo M, Allander T, Vuorinen T, Hedman K, Ruuskanen O: No efficacy of prednisolone in acute wheezing associated with human bocavirus infection. Pediatr Infect Dis J. 2011, 30:521-3. 10.1097/INF.0b013e2821e8d81
11. Abdel-Moneim AS, Kamel MM, Al-Ghamdi AS, Al-Malki MI: Detection of bocovirus in children suffering from acute respiratory tract infections in Saudi Arabia. PLoS One. 2013, 8:e55500. 10.1371/journal.pone.0055500
12. Proença-Modena JL, Martinez M, Amarilla AA, et al.: Viral load of human bocavirus-1 in stools from children with viral diarrhoea in Paraguay. Epidemiol Infect. 2015, 143:2576-80. 10.1017/S095026881300025X
13. Guido M, Quattrinchi M, Campa A, Zizza A, Grima P, Romano A, De Donno A: Human metapneumovirus and human bocavirus associated with respiratory infection in Apulian population. Virology. 2011, 417:64-70. 10.1016/j.virology.2011.04.016
14. Alam MM, Khurshid A, Shaukat S, et al.: ‘Human bocavirus in Pakistani children with gastroenteritis’ . J Med Virol. 2015, 87:656-65. 10.1002/jmv.24090
15. Kapoor A, Simmonds P, Silkas E, et al.: Human bocaviruses are highly diverse, dispersed, recombination prone, and prevalent in enteric infections. J Infect Dis. 2010, 201:1633-43. 10.1086/652416
16. Arthur JL, Higgins GD, Davidson GP, Givney RC, Ratcliff RM: A novel bocavirus associated with acute gastroenteritis in Australian children. PLoS Pathog. 2009, 5:e1000591. 10.1371/journal.ppat.1000591
17. Keserü D, Vazquez M, Weibel C, Shapiro ED, Ferguson D, Landry ML, Kahn JS: Human bocavirus infection in young children in the United States: molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. J Infect Dis. 2006, 194:1276-82. 10.1086/508213
18. Ma X, Endo R, Ishiguro N, Ebihara T, Ariga T, Kikuta H: Detection of human bocavirus in Japanese children with lower respiratory tract infections. J Clin Microbiol. 2006, 44:1152-4. 10.1128/JCM.44.3.1152-1154.2006
19. Bubshait DK, Aloluhi WH, Yousef AA, et al.: Clinical description of human bocavirus viremia in children with LRTI, Eastern Province, Saudi Arabia. Ann Thorac Med. 2015, 10:146-9. 10.4103/1817-1737.151437
20. Hindiyeh MY, Keller N, Mandelboim M, et al.: High rate of human bocavirus and adenovirus coinfection in hospitalized Israeli children. J Clin Microbiol. 2008, 46:334-7. 10.1128/JCM.01618-07
21. Tabani M, Mokhtari-Azag T, Eshraghian MR, Shadab A, Shatizadeh S, Shahferi-Jandaghi NZ, Yavarian J:...
Human bocavirus infections among children less than two years old in Iran during fall and winter 2012-2013. Iran J Microbiol. 2016, 8:80-4.

22. Zhou JY, Peng Y, Peng XY, et al.: Human bocavirus and human metapneumovirus in hospitalized children with lower respiratory tract illness in Changsha, China. Influenza Other Respir Viruses. 2018, 12:279-86. 10.1111/irv.12555

23. Liu WK, Chen DH, Liu Q, Liang HX, Yang ZF, Qin S, Zhou R: Detection of human bocavirus from children and adults with acute respiratory tract illness in Guangzhou, southern China. BMC Infect Dis. 2011, 11:345. 10.1186/1471-2334-11-345

24. Bastien N, Brandt K, Dust K, Ward D, Li Y: Human bocavirus infection, Canada. Emerg Infect Dis. 2006, 12:848-50. 10.3201/eid1205.051424

25. Kapoor A, Silkas E, Simmonds P, et al.: A newly identified bocavirus species in human stool. J Infect Dis. 2009, 199:196-200. 10.1086/595851

26. Fry AM, Lu X, Chittaganpitch M, et al.: Human bocavirus: a novel parvovirus epidemiologically associated with pneumonia requiring hospitalization in Thailand. J Infect Dis. 2007, 195:1038-45. 10.1086/512163

27. Kupfer B, Vehreschild J, Cornely O, et al.: Severe pneumonia and human bocavirus in adult. Emerg Infect Dis. 2006, 12:1614-6. 10.3201/eid1210.060520

28. Choi EH, Lee HJ, Kim SJ, et al.: The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000-2005. Clin Infect Dis. 2006, 43:585-92. 10.1086/506350

29. Lau SK, Yip CC, Que TL, et al.: Clinical and molecular epidemiology of human bocavirus in respiratory and fecal samples from children in Hong Kong. J Infect Dis. 2007, 196:986-93. 10.1086/521310

30. Arnold JC, Singh KK, Spector SA, Sawyer MH: Human bocavirus: prevalence and clinical spectrum at a children’s hospital. Clin Infect Dis. 2006, 43:283-8. 10.1086/505599